EUVIMEDEUVIMED entdecken
Open Access · CC BY 4.0

Rapid biotransformation of STW 5 constituents by human gut microbiome from IBS- and non-IBS donors

Timo A Thumann, Eva-Maria Pferschy-Wenzig iD, Christina Kumpitsch iD, Stefanie Duller iD, Christoph Högenauer, Patrizia Kump, Heba Aziz-Kalbhenn, Ramy M Ammar iD, Sabine Rabini iD, Christine Moissl-Eichinger iD, Rudolf Bauer iD

Microbiology Spectrum · 04.06.2024 · 12 (6)

DOI: 10.1128/spectrum.04031-23 ↗

Kurz gefasst

Fachartikel in der Zeitschrift Microbiology Spectrum, erschienen am 04.06.2024. Verfasst von Timo A Thumann und 10 weiteren Autor:innen. Beteiligte Einrichtung: Department of Pharmacognosy, Institute of Pharmaceutical Sciences, University of Graz, Graz, Austria. Hauptthemen laut MEDLINE: Irritable Bowel Syndrome, Gastrointestinal Microbiome, Feces, Biotransformation. Die Arbeit wurde bisher 5-mal zitiert (Crossref) und nennt 80 Literaturangaben. Der Volltext ist frei zugänglich (Open Access, CC BY 4.0).

AbstractSchlagwörterBibliografische AngabenZitierenVerwandte Studien

Abstract (Originalsprache)

STW 5, a blend of nine medicinal plant extracts, exhibits promising efficacy in treating functional gastrointestinal disorders, notably irritable bowel syndrome (IBS). Nonetheless, its effects on the gastrointestinal microbiome and the role of microbiota on the conversion of its constituents are still largely unexplored. This study employed an experimental ex vivo model to investigate STW 5’s differential effects on fecal microbial communities and metabolite production in samples from individuals with and without IBS. Using 560 fecal microcosms (IBS patients, n = 6; healthy controls, n = 10), we evaluated the influence of pre-digested STW 5 and controls on microbial and metabolite composition at time points 0, 0.5, 4, and 24 h. Our findings demonstrate the potential of this ex vivo platform to analyze herbal medicine turnover within 4 h with minimal microbiome shifts due to abiotic factors. While only minor taxonomic disparities were noted between IBS- and non-IBS samples and upon treatment with STW 5, rapid metabolic turnover of STW 5 components into specific degradation products, such as 18β-glycyrrhetinic acid, davidigenin, herniarin, 3-(3-hydroxyphenyl)propanoic acid, and 3-(2-hydroxy-4-methoxyphenyl)propanoic acid occurred. For davidigenin, 3-(3-hydroxyphenyl)propanoic acid and 18β-glycyrrhetinic acid, anti-inflammatory, cytoprotective, or spasmolytic activities have been previously described. Notably, the microbiome-driven metabolic transformation did not induce a global microbiome shift, and the detected metabolites were minimally linked to specific taxa. Observed biotransformations were independent of IBS diagnosis, suggesting potential benefits for IBS patients from biotransformation products of STW 5. IMPORTANCE STW 5 is an herbal medicinal product with proven clinical efficacy in the treatment of functional gastrointestinal disorders, like functional dyspepsia and irritable bowel syndrome (IBS). The effects of STW 5 on fecal microbial communities and metabolite production effects have been studied in an experimental model with fecal samples from individuals with and without IBS. While only minor taxonomic disparities were noted between IBS- and non-IBS samples and upon treatment with STW 5, rapid metabolic turnover of STW 5 components into specific degradation products with reported anti-inflammatory, cytoprotective, or spasmolytic activities was observed, which may be relevant for the pharmacological activity of STW 5.

Schlagwörter

MeSH-Schlagwörter (MEDLINE)

Irritable Bowel SyndromeGastrointestinal MicrobiomeFecesBiotransformationPlant ExtractsHumansAdultMaleFemaleBacteriaMiddle AgedPlants, Medicinal

Stichwörter der Autor:innen

IBSSTW 5UHPLC-HRMSmetabolomicsmicrobiomenext-generation sequencing

Substanzen

Plant Extracts

Autor:innen und Institutionen

  • Department of Pharmacognosy, Institute of Pharmaceutical Sciences, University of Graz, Graz, Austria.
  • BioTechMed, Graz, Austria.
  • Diagnostic and Research Institute of Hygiene, Microbiology and Environmental Medicine, Medical University of Graz, Graz, Austria.
  • Department of Internal Medicine, Medical University of Graz, Graz, Austria.
  • Steigerwald Arzneimittelwerk GmbH, Bayer Consumer Health, Darmstadt, Germany.
  • Department of Pharmacology, Faculty of Pharmacy, Kafrelsheikh University, Kafrelsheikh, Egypt.

ORCID-Profile: Eva-Maria Pferschy-Wenzig, Christina Kumpitsch, Stefanie Duller, Ramy M Ammar, Sabine Rabini, Christine Moissl-Eichinger, Rudolf Bauer

Zitieren

APA

Thumann, T. A., Pferschy-Wenzig, E. M., Kumpitsch, C., Duller, S., Högenauer, C., Kump, P., Aziz-Kalbhenn, H., Ammar, R. M., Rabini, S., Moissl-Eichinger, C., & Bauer, R. (2024). Rapid biotransformation of STW 5 constituents by human gut microbiome from IBS- and non-IBS donors. Microbiology Spectrum, 12(6). https://doi.org/10.1128/spectrum.04031-23

Vancouver

Thumann TA, Pferschy-Wenzig EM, Kumpitsch C, Duller S, Högenauer C, Kump P, et al. Rapid biotransformation of STW 5 constituents by human gut microbiome from IBS- and non-IBS donors. Microbiology Spectrum. 2024;12(6). doi:10.1128/spectrum.04031-23

BibTeX
@article{Thumann2024,
  author = {Thumann, Timo A and Pferschy-Wenzig, Eva-Maria and Kumpitsch, Christina and Duller, Stefanie and Högenauer, Christoph and Kump, Patrizia and Aziz-Kalbhenn, Heba and Ammar, Ramy M and Rabini, Sabine and Moissl-Eichinger, Christine and Bauer, Rudolf},
  title = {Rapid biotransformation of STW 5 constituents by human gut microbiome from IBS- and non-IBS donors},
  journal = {Microbiology Spectrum},
  year = {2024},
  volume = {12},
  number = {6},
  doi = {10.1128/spectrum.04031-23}
}
Kostenlos starten →